PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | – | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $469 | $0 | – | $1,667 |
| Gross Profit | -$469 | $0 | – | -$1,667 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,010 | $3,325 | – | -$470 |
| G&A Expenses | $0 | $2,961 | – | $1,343 |
| SG&A Expenses | $4,831 | $2,961 | – | $1,343 |
| Sales & Mktg Exp. | $0 | $0 | – | $0 |
| Other Operating Expenses | $0 | $0 | – | $0 |
| Operating Expenses | $11,841 | $5,757 | – | -$2,677 |
| Operating Income | -$12,310 | -$5,749 | – | $2,678 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $228 | $60 | – | -$62 |
| Pre-Tax Income | -$12,082 | -$5,689 | – | $2,616 |
| Tax Expense | -$795 | $1 | – | -$3,318 |
| Net Income | -$11,287 | -$5,690 | – | $5,935 |
| % Margin | – | – | – | – |
| EPS | -1.72 | 0 | – | 0.19 |
| % Growth | – | – | – | – |
| EPS Diluted | -1.72 | 0 | – | 0.19 |
| Weighted Avg Shares Out | 6,573 | 0 | – | 31,016 |
| Weighted Avg Shares Out Dil | 6,573 | 0 | – | 31,016 |
| Supplemental Information | – | – | – | – |
| Interest Income | $88 | $294 | – | $422 |
| Interest Expense | $93 | $314 | – | $483 |
| Depreciation & Amortization | $469 | $263 | – | $1,667 |
| EBITDA | -$11,520 | -$5,486 | – | -$6,495 |
| % Margin | – | – | – | – |